肝病肌肉减少症发病机制研究进展*

doi:10.3969/j.issn.1672-5069.2022.02.038

Abstract

Abstract: Objective Sarcopenia is defined as loss of systemic skeletal muscle mass and functions. It may affect the physiological functions and leads to the declined quality of life, and even death. Sarcopenia occurs in up to 70% of patients with advanced liver diseases, which is associated with untoward clinical outcomes and poor prognosis. At present, most treatments are based on nutrition and exercise, however, there is still a lack of effective targeted molecular therapy. This review summarizes the pathogenesis of sarcopenia in liver diseases, in order to identify potential biomarkers for treatment and improve the clinical prognosis.

Key words: Liver diseases, Sarcopenia, Pathogenesis

Lin Ning, Kong Ming, Duan Zhongping. Pathogenesis of sarcopenia in liver diseases[J]. Journal of Practical Hepatology, 2022, 25(2): 301-304.

References

[1] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world.J Hepatol,2019,70(1):151-171.
[2] Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis.Aliment Pharmacol Ther,2020,51(1):64-77.
[3] Meyer F, Bannert K, Wiese M,et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis. Int J Mol Sci,2020, 21(15):5357.
[4] Kang SH, Jeong WK, Baik SK,et al. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle,2018,9(5):860-870.
[5] Ooi PH, Gilmour SM, Yap J,et al. Effects of branched chain amino acid supplementation on patient care outcomes in adults and children with liver cirrhosis: A systematic review. Clin Nutr ESPEN,2018,28:41-51.
[6] Les I, Doval E, García-Martínez R,et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study.Am J Gastroenterol,2011,106(6):1081-1088.
[7] Bojko M. Causes of sarcopenia in liver cirrhosis.Clin Liver Dis (Hoboken),2019, 14(5):167-170.
[8] Khoshnood A, Nasiri Toosi M, Faravash MJ,et al. A survey of correlation between insulin-like growth factor-I (igf-I) levels and severity of liver cirrhosis. Hepat Mon,2013,13(2):e6181.
[9] Ibebunjo C, Eash JK, Li C, et al. Voluntary running, skeletal muscle gene expression, and signaling inversely regulated by orchidectomy and testosterone replacement.Am J Physiol Endocrinol Metab,2011,300(2):E327-340.
[10] Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.J Hepatol,2016,65(5):906-913.
[11] Qiu J, Thapaliya S, Runkana A,et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism.Proc Natl Acad Sci U S A,2013,110(45):18162-18167.
[12] Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease.J Hepatol,2016,65(6):1232-1244.
[13] Qiu J, Tsien C, Thapalaya S, et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis.Am J Physiol Endocrinol Metab,2012,303(8):E983-E993.
[14] Mcdaniel J, Davuluri G, Hill EA, et al. Hyperammonemia results in reduced muscle function independent ofmuscle mass.Am J Physiol Gastrointest Liver Physiol, 2016,310(3):G163-G170.
[15] Campos F, Abrigo J, Aguirre F, et al. Sarcopenia in a mice model of chronic liver disease: role of the ubiquitin-proteasome system and oxidative stress. Pflugers Arch,2018,470(10):1503-1519.
[16] 肖慧娟,张明,齐玉梅,等.肌肉减少症与慢性肝脏病的研究进展.中华肝脏病杂志, 2019,27(7):563-566.
[17] Da Rocha AL, Pinto AP, Morais GP, et al. Moderate, but not excessive, training attenuates autophagy machinery in metabolic tissues.Int J Mol Sci,2020,21(22):8416.
[18] Mangner N, Linke A, Oberbach A, et al. Exercise training prevents TNF-αinduced loss of force in the diaphragm of mice.PLoS One,2013,8(1):e52274.
[19] Ticinesi A, Lauretani F, Tana C, et al. Exercise and immune system as modulators of intestinal microbiome: implications for the gut-muscle axis hypothesis.Exerc Immunol Rev,2019,25:84-95.
[20] Yan J, Herzog JW, Tsang K, et al. Gut microbiota induce IGF-1 and promote bone formation and growth.Proc Natl Acad Sci USA,2016,113(47):E7554-E7563.
[21] Dasarathy J, Mccullough AJ, Dasarathy S. Sarcopenia in alcoholic liver disease: clinical and molecular advances. Alcohol Clin Exp Res,2017,41(8):1419-1431.
[22] Bonet-Ponce L, Saez-Atienzar S, Da CC, et al. On the mechanism underlying ethanol-induced mitochondrial dynamic disruption and autophagy response. Biochim Biophys Acta,2015,1852(7):1400-1409.
[23] NammiS, Roufogalis BD. Light-to-moderate ethanol feeding augments AMPK-alpha phosphorylation and attenuates SREBP-1 expression in the liver of rats.J Pharm Pharm Sci,2013,16(2):342-351.
[24] Hong-Brown LQ, Brown CR, Kazi AA, et al. Rag GTPases and AMPK/TSC2/Rheb mediate the differential regulation of mTORC1 signaling in response to alcohol and leucine.Am J Physiol Cell Physiol,2012,302(10):C1557-C1565.
[25] Chiang JY.Bileacid metabolism and signaling.Compr Physiol,2013,3(3):1191-1212.
[26] Abrigo J, Gonzalez F, Aguirre F, et al. Cholic acid and deoxycholic acid induce skeletal muscle atrophy through a mechanism dependent on TGR5 receptor.J Cell Physiol,2021,236(1):260-272.
[27] Tanaka M, Okada H, Hashimoto Y, et al. Relationship between nonalcoholic fatty liver disease and muscle quality as well as quantity evaluated by computed tomography.Liver Int,2020,40(1):120-130.
[28] Hsieh YC, Joo SK, Koo BK, et al. Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease. Liver Int,2021,41(3):494-504.
[29] Conte M, Armani A, Conte G, et al. Muscle-specificperilipin 2 down-regulation affects lipid metabolism and induces myofiber hypertrophy.J Cachexia Sarcop Muscl,2019,10(1):95-110.
[30] Pravisani R, Soyama A, Isola M, et al. Chronological changes in skeletal muscle mass following living-donor liver transplantation: An analysis of the predictive factors for long-term post-transplant low muscularity.Clin Transplant,2019,33(4):e13495.
[31] Kallwitz ER.Sarcopenia and liver transplant: The relevance of too little muscle mass.World J Gastroenterol,2015,21(39):10982-10993.

Pathogenesis of sarcopenia in liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Ping, Yao Dengfu, Yao Min. Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 157-160.
[2]	Chen Kai, Ju Feng. Observation of hepatic steatosis score by ultrasonography in patients with nonalcoholic fatty liver diseases after polyene phosphatidylcholineand Fuzheng Huayu capsule combination treatment [J]. Journal of Practical Hepatology, 2022, 25(2): 219-222.
[3]	Liang Yebei, Yang Chunguang, Wang Kunfeng, et al. Epidemiologic investigation of non-alcoholic fatty liver diseases in whole adults of Blang ethnicity in Yunnan province [J]. Journal of Practical Hepatology, 2022, 25(2): 223-226.
[4]	Li Wei, Huang Yu, Zhong Jing, et al. Correlation of PNPLA3 rs738409 gene polymorphism to genetic susceptibility of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 227-230.
[5]	Mo Chaoyan, Yang Youqiang, Zhong Yuan, et al. Implication of serum resistin and retinol-binding protein 4 in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2022, 25(2): 231-234.
[6]	Huang Die, Tian Haoyu, Li Yiling. Serum markers in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 297-300.
[7]	Feng Yu, Du Zhenyuan, Li Yanbin, et al. Serum IL-17 levels and single nucleotide polymorphism of its gene at -197A/G locus in patients with alcoholic liver diseases [J]. Journal of Practical Hepatology, 2022, 25(1): 58-61.
[8]	Zhu Nannan, Jiang Xiaohong, Zhou Jiayan, et al. Serum uric acid levels and its clinical implications in patients with diabetes mellitus type 2 and concomitant metabolism-related fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(6): 839-842.
[9]	Ge Haiyan, Kuang Xia, Zhou Ruijun. Changes of serum miR-17, miR-20a and miR-20b levels in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(5): 697-700.
[10]	Xu Xiangtao, Qiao Fei, Che Junyong, et al. Short-term efficacy of Huazhuo Tongyu decoction in the treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(5): 701-704.
[11]	Ma Shangji, Zheng Yang, Chen Xufeng, et al. Clinical feature and risk factors of elderly patients with nonalcoholic fatty liver diseases and concomitant coronary heart disease [J]. Journal of Practical Hepatology, 2021, 24(5): 705-708.
[12]	Liu Lixia, Lin Yingyuan, Li Huamin, et al. Comparative study on the clinical efficacy of lorazepam and oxazepam in treatment of patients with alcoholic liver diseases and alcohol withdrawal syndrome [J]. Journal of Practical Hepatology, 2021, 24(5): 709-712.
[13]	Wang Qixia, Ma Xiong. Insights to precision medicine and clinical translational research in patients with autoimmune liver diseases [J]. Journal of Practical Hepatology, 2021, 24(4): 457-459.
[14]	Zhang Jia, Jin Mingyuan, Du Yanyun, et al. Serum cytokine changes in patients with nonalcoholic fatty liver diseases and helicobacter pylori infection after clearance therapy [J]. Journal of Practical Hepatology, 2021, 24(4): 500-503.
[15]	Feng Juan, Halida Xiaerfuhazi, Fan Xiaotang, et al. Serum leptin level in patients with hepatitis B liver cirrhosis and concomitant metabolic associated fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(4): 536-539.